TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01121653
Drug: Magnogene ® (magnesium)
Approvals — FDA: no, EMA: no, PMDA: no
Description: evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
Study: NCT00717093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Study: NCT01259128
Drug: SER120 Nasal Spray 500 ng/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER120 Level 1
Study: NCT01259128
Drug: SER120 nasal spray 750 ng/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER120 (750 ng/day)
Study: NCT02555878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet will be administered orally once daily for 180 days.
Study: NCT03625622
Drug: AR1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR1001 Active Oral Tablet
Study: NCT03625622
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
Study: NCT03235778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
Study: NCT02543710
Drug: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression.
Study: NCT01492361
Drug: AMR101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel Assignment
Study: NCT01492361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel Assignment
Study: NCT01492361
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable statin therapy (± ezetimibe) for at least 28 days before lipid qualification measurement (LDL-C \>40 mg/dL and ≤100 mg/dL)
Study: NCT04696757
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine without surgery
Study: NCT03527745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets will be obtained from Fagron, Germany.
Study: NCT02574091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for twice daily.
Study: NCT03120000
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Study: NCT00622817
Drug: Epinephrine 1mg
Normalized name: EPINEPHRINE 1MG/ML INJ
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
Study: NCT05988008
Drug: CCX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05988008
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00536679
Drug: GSK163090 capsule, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
Study: NCT00536679
Drug: GSK163090 Tablet, fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
Study: NCT00536679
Drug: GSK163090 Tablet, fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
Study: NCT03109249
Drug: SPARC1613
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
Study: NCT03109249
Drug: Reference1613
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
Study: NCT00533897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
Study: NCT01270516
Drug: HMB, hydroxymethylbutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
Study: NCT01270516
Drug: EPA, eicosapentaenoic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
Study: NCT04188847
Drug: Chemotherapy plus apatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of cisplatin, paclitaxel and apatinib would be given for all patients:~* Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks. If the creatinine clearance rate was less than 40 ml/min, the cisplatin would be replace by carboplatin (area under ther curve = 5)~* Paclitaxel: 50 mg/m2 body surface area, on the first day, every 3 weeks~* Apatinib: 250 mg every day The total courses of cisplatin and paclitaxel would be no more than 6.
Study: NCT02227862
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
Study: NCT02314546
Drug: saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - Control patients will receive intranasal saline.
Study: NCT00587457
Drug: CAT-8015 5 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study: NCT00587457
Drug: CAT-8015 10 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study: NCT00587457
Drug: CAT-8015 20 mcg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study: NCT02994992
Drug: BAY 987516
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z46-100)
Study: NCT01774474
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01106495
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
Study: NCT00763022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Study: NCT02994992
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT00125424
Drug: AQUAVAN® (fospropofol disodium) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02019810
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02019810
Drug: Dobutamine and norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03643796
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
Study: NCT03423641
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
Study: NCT02371304
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02585843
Drug: Spironolactone 100mg
Normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 capsules of study medication consist of 100mg, PO (oral) for 7 days
Study: NCT02585843
Drug: Spironolactone 25mg
Normalized name: SPIRONOLACTONE 25MG TAB
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/day of spironolactone
Study: NCT00977106
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single iv infusion
Study: NCT00354887
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine 750 mg/m\^2 twice daily (total daily dose 1500 mg/m\^2) on Days 1-14 in 21 Day Cycle.
Study: NCT04736693
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid dispensing claim is used as the exposure group.
Study: NCT00575406
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v., 750 mg/m2, d1 of each treatment cycle
Study: NCT00575406
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Study: NCT00575406
Drug: liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v., 50 mg/m2, d1 of each treatment cycle
Study: NCT00575406
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p.o., 100mg, d1 - d5 of each treatment cycle
Study: NCT03577509
Drug: ABCD
Normalized name: Pentavalent (ABCDE) botulinum toxoid vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
Study: NCT00003078
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01261078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal 8 mg of bupivacaine only
Study: NCT01261078
Drug: epinephrine 25
Normalized name: EPINEPHRINE 250MCG 300D ORAL INHL
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
Study: NCT01261078
Drug: Epinephrine 50
Normalized name: epinephrine 500 MCG per 0.5 ML Injectable Solution
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
Study: NCT01261078
Drug: epinephrine 100
Normalized name: Epinephrine 100 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
Study: NCT02153398
Drug: D961H capsule 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02153398
Drug: D961H capsule 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00900237
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
Study: NCT03535168
Drug: BAY1902607
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 different doses over the course of part 1 and 4 different doses over the course of part 2.
Study: NCT03535168
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BAY1902607
Study: NCT00459225
Drug: Iron (ferrous sulfate)
Normalized name: Iron (Ferrous Sulfate)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
Study: NCT01475838
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTV administered according to prescribing information FTC/TDF administered according to prescribing information
Study: NCT01475838
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF (200/300 mg) administered according to prescribing information
Study: NCT04168957
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets
Study: NCT00602329
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00602329
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03236857
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
Study: NCT02652754
Drug: Granexin® gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
Study: NCT01400425
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection, 370 megabecquerel (MBq) (10 millicurie \[mCi\]), single dose
Study: NCT03204578
Drug: AB (Midazolam OD formulation/Dormicum)
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
Study: NCT02194465
Drug: LY2623091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02194465
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02194465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01898416
Drug: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
Study: NCT02480296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01373164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02433678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00631033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01605903
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Study: NCT01605903
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Study: NCT02385318
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00769392
Drug: Proparacaine Ophthalmic
Normalized name: proparacaine ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drops of Proparacaine on the eye, administered as described in the package insert
Study: NCT00082563
Drug: Azithromycin/Chloroquine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00806156
Drug: NKTR-102 q14d
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 given on a q14 day schedule
Study: NCT00806156
Drug: NKTR-102 q21d
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-102 given on a q21 day schedule
Study: NCT01463488
Drug: SAR113945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT01463488
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection~Route of administration: Intra-articular
Study: NCT01634906
Drug: Temporary discontinuation of statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
Study: NCT00423605
Drug: Xyrem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: flexible dosing
Study: NCT00396292
Drug: Oral iron tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
Study: NCT01521546
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg tablet, once daily by mouth for 12 months
Study: NCT01521546
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet by mouth daily for 12 months
Study: NCT01205204
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
Study: NCT03977480
Drug: Hemay007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemay007 will be orally administered.
Study: NCT02651636
Drug: myo-inositol,alpha-lipoic acid and folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03977480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02606305
Drug: Pegylated Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00154180
Drug: Transdermal estradiol, 50 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
Study: NCT00154180
Drug: CEE , progesterone, estradiol patch or placebo for each
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
Study: NCT01951846
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV to maintain the blind.
Study: NCT00107393
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01939197
Drug: ABT-450/r/ABT-267
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01939197
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01834963
Drug: Interferon Alfa、Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks
Study: NCT01834963
Drug: Cisplatin、Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks
Study: NCT00593502
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of placebo will be similar to the active drug